Asenapine: Transdermal vs Sublingual?
ASENAPINE:
TRANSDERMAL VS SUBLINGUAL
This post will summarize the key differences between the transdermal and sublingual formulation of asenapine in the following 10 minutes of video discussion.
SUMMARY:
FDA approved the transdermal asenapine formulation (SECUADO®) in 2019 and here is our website post from Oct 2019 summarizing this formulation in the following sections:
- Indication
- Dosing & Administration
- Application Sites
- Dose Conversion from Oral Asenapine
- Contraindications
- Laboratory workup.Investigations
- Drug Interactions
REFERENCES:
- Noven Pharmaceuticals, Inc. Media Press Release.
- Carrithers, B., & El-Mallakh, R. S. (2020). Transdermal Asenapine in Schizophrenia: A Systematic Review. Patient preference and adherence, 14, 1541–1551. (pubmed)
- SECUADO® (asenapine) transdermal system package insert. (PDF)
INTERESTED IN LEARNING MORE?
JOIN PSYCHIATRY EDUCATION FORUM ACADEMY MEMBERSHIP
This is a closed membership for medical professionals only.
- 30+ Courses/Sections: Each chapter within these sections is of direct clinical relevance for your daily practice.
- Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice.
- Coffee Club: contain short discussions with clinical experts in the field of psychiatry.
- Essentials of Inpatient Psychiatry Book: All chapters from this book are included in the academy sections.
- Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases.
- Conference Discounts: Academy members get discounted access at our conferences.
- Goal: is to have all important clinically relevant topics in one place for ease of access.
